Yu-Hung Wang

I can scarcely believe I’m soon to leave 🇬🇧, a country that has shaped me in ways I’m only beginning to understand. Grateful beyond words to colleagues and friends. Though I must depart for now, I shall return.

Six months of clinics with Dan and Tim respectively. Did see quite a few truly special MDS/MPN/AYA cases (a real strength of the UK’s specialist system vs a broader practice in Taiwan). In a fortnight I’ll be on my own but these times and experiences will always be appreciated.

READ THE MAIN SCIENTIFIC TOPICS OF #ESHMPN2026! 11th Translational Research Conference Myeloproliferative Neoplasms April 24-26, 2026/Estoril, Portugal Chairs:@jjkiladjian @rosslevinemd @MullallyLab @jyoti_nangalia More information➡️bit.ly/4litFm1 #ESHCONFERENCES #MPNsm

👉👉👉Efficacy of a novel #BCL-xL degrader, #DT2216, in preclinical models of #JAK2-mutated post-MPN AML | ⁦@BloodPortfolio⁩ | ⁦@ASH_hematology⁩ | ⁦@mkonople⁩ ⁦@doctorpemm⁩ #MPNSM #leusm ashpublications.org/blood/article/…

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia - PubMed ⁦@MDAndersonNews⁩ ⁦@MayoCancerCare⁩ ⁦@BloodPortfolio⁩ GMB ⁦@sanamloghavi⁩ ⁦@doctorpemm⁩ ⁦@ccsizmar⁩ #CMML #RAS pubmed.ncbi.nlm.nih.gov/40644618/

1266 Chronic Myelomonocytic Leukemia in Younger Patients Demonstrates Different Clinical and Molecular Genetic Features laboratoryinvestigation.org/article/S0023-… #CMML #MDSsm #MPNsm @MrinalPatnaik @MDSFoundation @MDS_Hub @ic_MDS @aamdsif

🚨 New paper in @NatureGenet ! How does cancer chemotherapy reshape the HSC landscape and drive the evolution of therapy-related myeloid neoplasms? We uncovered this process through single-colony WGS! See the full paper here! nature.com/articles/s4158…

RAS Mutation Identifies a Poor Prognostic Molecular Subtype of Therapy-Related Myeloid Neoplasm - PubMed ⁦@MayoCancerCare⁩ #RAS pubmed.ncbi.nlm.nih.gov/40402688/

Clinical management of CMML—State of the art |British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj… #leusm #MDS #CMML

Our Lab together with Amos Tanay lab has created the first reference model for HSPCs published in Nature Medicine yesterday. doi.org/10.1038/s41591… you can look at the data here (really nice tool) apps.tanaylab.com/MCV/blood_aging

In the future we will use this model to replace bone marrow this is how a report will look like

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia #CMML #TET2 @ccsizmar @MayoCancerCare @MDAndersonNews pubmed.ncbi.nlm.nih.gov/40555734/

📣#ESHMPN2026: CALL FOR ABSTRACTS! 11th Translational Research Conference Myeloproliferative Neoplasms To proceed & for more information 👉bit.ly/4litFm1 Chairs:@jjkiladjian @rosslevinemd @MullallyLab @jyoti_nangalia April 24-26, 2026 in Estoril 🇵🇹 #ESHCONFERENCES #MPNsm

Honoured and grateful to receive the Highly Commended Doctoral Academy’s Best Outstanding Research Contribution Award. My sincere thanks to my supervisors, Dan and Kiran, for their invaluable guidance over the years and for nominating me for this competitive award. @Kiran_Batta

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome are now well established as their own unique diagnostic entity, characterized by an exceptionally poor prognosis and inadequate therapeutic options. ow.ly/XMBu50WagUw #BloodSpotlight #myeloidneoplasia

With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…